The PARP Inhibitor market is a subset of the Oncology Drugs market, focusing on drugs that inhibit the enzyme poly (ADP-ribose) polymerase (PARP). PARP inhibitors are used to treat certain types of cancer, such as ovarian, breast, and prostate cancer. These drugs work by blocking the activity of PARP, which helps cancer cells repair their DNA and survive. This makes them an effective treatment for cancers that have become resistant to other treatments. PARP inhibitors are a relatively new class of drugs, and the market is still in its early stages. However, the potential of these drugs has attracted the attention of many pharmaceutical companies, and several have developed their own PARP inhibitors. Companies such as AstraZeneca, Clovis Oncology, and Tesaro have all developed PARP inhibitors that are currently approved for use in the United States. Other companies, such as Merck and Pfizer, are also developing PARP inhibitors that are currently in clinical trials. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
